IAI FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
IAI.01727-06v1
75/4/2067    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Quin, L. R.
Right arrow Articles by McDaniel, L. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Quin, L. R.
Right arrow Articles by McDaniel, L. S.

 Previous Article  |  Next Article 

Infection and Immunity, April 2007, p. 2067-2070, Vol. 75, No. 4
0019-9567/07/$08.00+0     doi:10.1128/IAI.01727-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Pneumolysin, PspA, and PspC Contribute to Pneumococcal Evasion of Early Innate Immune Responses during Bacteremia in Mice{triangledown}

Lisa R. Quin,1 Quincy C. Moore III,1 and Larry S. McDaniel1,2,3*

Departments of Microbiology,1 Surgery,2 Medicine, The University of Mississippi Medical Center, Jackson, Mississippi 392163

Received 27 October 2006/ Returned for modification 15 December 2006/ Accepted 4 January 2007


   ABSTRACT
Top
 Abstract
Text
 References
 
The pneumococcal virulence factors include capsule, PspA, PspC, and Ply. Cytometric analysis demonstrated that the greatest levels of C3 deposition were on a {Delta}ply PspA– PspC– mutant. Also, Ply, PspA, and PspC expression resulted in C3 degradation in vitro and in vivo. Finally, blood clearance assays demonstrated that there was enhanced clearance of {Delta}ply PspA– PspC– pneumococci compared to the clearance of nonencapsulated pneumococci.


   TEXT
Top
 Abstract
 Text
References
 
Streptococcus pneumoniae possesses virulence factors that function in evasion of complement (3, 27-29). The capsular polysaccharide (CPS) is considered a key factor in complement resistance (13, 21), and the interaction of pneumococci with complement varies according to the CPS type (1, 15, 19). Ply can activate the classical pathway, diverting complement activation (26, 29). Pneumococcal surface protein A (PspA) can also interfere with complement deposition, blocking recruitment of alternative pathway (AP) proteins (4, 24). Pneumococcal surface protein C (PspC; also called CbpA and SpsA) interacts with factor H (7, 22). Factor H regulates the AP by serving as a cofactor during factor I-mediated cleavage of C3b to iC3b (10, 11, 16, 25). Studies have demonstrated that more C3b is deposited on nonencapsulated pneumococci (30) and on PspA– or Ply– strains (24, 31). PspC mutants are less able to inhibit AP activation (17) and have reduced virulence (9). We investigated C3 deposition, complement inactivation, and blood clearance of pneumococci in the absence of Ply, PspA, and PspC.

Pneumococcal strains, growth conditions, and CPS determination. The pneumococci used are listed in Table 1 and include R36A, D39, and isogenic mutants of D39. LM91, TRE108, and TRE121 are insertion-duplication mutants, and {Delta}PLY2 and {Delta}PAC (generated for this study by deleting ply of TRE121) were generated by allelic replacement (29). Bacteria were grown to mid-log phase as described previously (22). When necessary, erythromycin (0.5 µg/ml), tetracycline (15 µg/ml), and trimethoprim (50 µg/ml) were added to media.


View this table:
[in this window]
[in a new window]

  		TABLE 1. Pneumococcal strains used in complement deposition and virulence studies

 
To investigate the combined role of Ply, PspA, and PspC in C3 deposition, we generated {Delta}PAC. Experiments with {Delta}PAC were repeated using independent clones from different transformations to ensure that the results were not due to inadvertent mutations. Growth curves demonstrated that growth of D39 and growth of {Delta}PAC were similar (not shown). The amount of CPS was determined by an enzyme-linked immunosorbent assay as previously described (8), using an anti-CPS type 2 monoclonal antibody, monoclonal antibody 2G1 (provided by M. H. Nahm). D39 and mutants of this strain had similar levels of CPS. The endpoint titers for D39, {Delta}PAC, and TRE121 were 1,160 ± 655, 1,350 ± 540, and 1,340 ± 530 (means ± standard errors of the means), respectively; these values were significantly different (P = 0.03) from the value for R36A (≤10). CPS of pneumococci was also detected by flow cytometry (fluorescence-activated cell sorting; FACScan cytometer; Becton Dickinson) as described previously (22) using monoclonal antibody 2G1, which demonstrated that CPS was present on viable D39 and {Delta}PAC (not shown). The capsules of D39 and {Delta}PAC were visualized following staining with Alcian Blue 8GX (Sigma) by transmission electron microscopy as described previously (14) (Fig. 1).


Figure 1
View larger version (60K):
[in this window]
[in a new window]

  		FIG. 1. Detection of type 2 CPS: electron micrographs of D39 (A), {Delta}PAC (B), and R36A (C) stained with Alcian Blue to visualize pneumococcal CPS (indicated by arrows).

 
C3 deposition on the pneumococcal surface. C3 deposition assays were performed as described previously (24), except that pneumococci (105 CFU/ml) were incubated with normal human serum (NHS) (CompTech) as a complement source. C3 was then detected using goat anti-human C3-biotinylated (1:100 dilution) (CompTech) and strepavidin-conjugated Alexa Fluor 488 (Molecular Probes). Fluorescence-activated cell sorting was used to calculate the percentage of C3-positive bacteria and mean fluorescence intensities (MFI). The results demonstrated that the percentages of {Delta}PAC, TRE121, and single mutants that were C3 positive were consistently greater than the percentage of D39 that was C3 positive (Fig. 2A). The MFI of D39, LM91, TRE108, {Delta}PLY2, TRE121, R36A, and {Delta}PAC were 7.8 ± 4, 57.7 ± 7, 71.3 ± 8, 75.7 ± 5, 102 ± 16.1, 138 ± 39.5, and 468.4 ± 50, respectively. Histograms demonstrated that more C3 was present on {Delta}PAC (Fig. 2B). These data support the findings of other studies that demonstrated the synergistic roles of Ply and PspA in complement inhibition (31) and suggest that in the absence of virulence proteins, pneumococci are more vulnerable to complement than a nonencapsulated strain is.


Figure 2
View larger version (30K):
[in this window]
[in a new window]

  		FIG. 2. Detection of C3 deposition on the surface of pneumococci using flow cytometry analysis. (A) Percentages of the populations that were positive for C3 deposition. Student's t test was used to compare C3 deposition data, and a P value of <0.05 was considered significant. The P values for comparisons with D39 were as follows: R36A, P = 0.0001; {Delta}PAC, P = 0.0002; TRE121, P = 0.006; LM91, P = 0.013; TRE108, P = 0.02; and {Delta}PLY2, P = 0.01. (B) Representative histograms for C3 deposition on D39 (MFI, 7.8 ± 4.0 [mean ± standard error for three or more independent experiments]), R36A (138 ± 39.5), TRE121 (102 ± 16.1), and {Delta}PAC (468.4 ± 50). The fluorescence intensity of C3 detected on encapsulated {Delta}PAC was significantly greater (P = 0.007) than that detected on nonencapsulated R36A.

 
In vitro and in vivo C3 processing by pneumococci expressing Ply, PspA, and PspC. We first investigated the role of Ply, PspA, and PspC in complement inactivation using in vitro C3 degradation assays. Western analysis was performed as described previously to detect iC3b (6, 23), except that pneumococci (105 CFU/ml) were incubated with 20% NHS for 30 min at 37°C. C3 fragments in supernatants were analyzed by Western blotting using an anti-human iC3b monoclonal antibody (Quidel). This antibody detects generation of iC3b, which serves as an indicator of AP activity. The remaining incubation procedures were performed as described previously (6, 23). Degradation of C3b to iC3b resulted in the appearance of 75- and 40-kDa fragments. With D39 and R36A we detected degradation of human C3b (109 kDa) to iC3b, as indicated by the appearance of 75- and 40-kDa bands. TRE121 exhibited some ability to degrade C3b, whereas {Delta}PAC was unable to cleave C3b as efficiently as the other strains (Fig. 3A). These results suggest that Ply, PspA, and PspC function cooperatively to degrade C3b on the pneumococcal surface.


Figure 3
View larger version (68K):
[in this window]
[in a new window]

  		FIG. 3. Western blot analysis of pneumococci following complement inactivation assays. (A) Following incubation with NHS, activated human C3b (represented by the band at 109 kDa) and its cleaved fragments, iC3b (represented by bands at 75 and 40 kDa), were detected using an anti-iC3b monoclonal antibody. D39 (lane 1), R36A (lane 2), and TRE121 (lane 3) exhibited enhanced cleavage of C3b to iC3b compared to the cleavage in {Delta}PAC (lane 4). (B) Following challenge of mice with 108 CFU of a strain, blood was collected at 5 min (lanes 1), 10 min (lanes 2), 20 min (lanes 3), and 30 min (lanes 4). C3 processing was detected using a mouse C3 antiserum. C3 (represented by bands at approximately 120 to 170 kDa) was detected in naïve mouse blood and in blood by 5 min after infection with {Delta}PAC, R36A, and D39. Degradation fragments of iC3b (corresponding to bands at approximately 70 and 43 kDa) were detected in D39- and R36A-infected mice by 10 min (lanes 2 to 4).

 
To demonstrate C3 processing in vivo, we used previously described methods (12), except that naïve CBA/N mice (Jackson Laboratories) were challenged intravenously with 108 CFU of D39, R36A, or {Delta}PAC suspended in 0.2 ml of lactated Ringer's solution. Blood samples were collected from mice by retroorbital bleeding at 5, 10, 20, and 30 min postinfection. Serum was collected and diluted 1:25 with 2x sodium dodecyl sulfate loading buffer, and 20 µl of each sample was used in a Western analysis as described previously (12) with polyclonal goat anti-mouse C3 (Immunology Consultants Laboratory). Figure 3B shows the C3, C3b, and inactivated fragments in mouse serum at 5, 10, 20, and 30 min after infection with different strains. C3 (bands at approximately 120 to 170 kDa) was detected in naïve mouse serum and in serum 5 min after infection with {Delta}PAC, R36A, and D39. iC3b was more evident in serum collected after challenge with D39 or R36A, as indicated by the presence of bands at approximately 70 and 43 kDa at 10 min. This pattern of C3 inactivation was not as evident after infection with {Delta}PAC. These observations supported the results of the in vitro C3 assays and further suggest that expression of Ply, PspA, and PspC, independent of the CPS, accelerates C3 inactivation that could enhance pneumococcal survival.

Pneumococcal clearance during infection. Clearance assays were performed as described previously (2, 18, 23), and groups of five CBA/N mice per challenge strain were infected intravenously with 2 x 104 CFU of pneumococci (Table 1). Blood was collected at zero time, 10 and 20 min, and 24 h. Pneumococci in blood were enumerated by plating serial dilutions on blood agar. Three independent experiments were performed, and all animal experiments were conducted by following the University of Mississippi Medical Center IACUC guidelines. We also monitored the mortality of mice for up to 21 days. Data from clearance assays demonstrated that mice challenged with D39 had the highest number of pneumococci in their blood at 24 h (Fig. 4). A significant reduction in the number of nonencapsulated pneumococci in the bloodstream occurred after 20 min, whereas the numbers of the combination mutants were significantly reduced by 10 min and at 20 min (Fig. 4). This indicates that in the absence of Ply, PspA, and PspC the type 2 CPS cannot effectively evade early innate responses and suggests that the rapid clearance of TRE121 and {Delta}PAC could be due to their inability to successfully evade complement deposition.


Figure 4
View larger version (22K):
[in this window]
[in a new window]

  		FIG. 4. Pneumococcal blood clearance assays. The numbers of CFU detected in the bloodstream following infection with TRE121 and following infection with {Delta}PAC were significantly reduced by 10 min (P = 0.003 [one asterisk] and P = 0.004 [two asterisks], respectively, for comparisons with R36A). The numbers of nonencapsulated R36A in the blood were significantly reduced by 20 min (P = 0.01 for a comparison with D39). Three independent experiments using groups of five mice per challenge strain were performed, and the mortality of mice was monitored for 21 days after infection. Mice challenged with D39 succumbed to infection by 36 h, and mice challenged with pneumococci lacking only one of the virulence proteins succumbed to infection between 48 and 72 h after infection. The values are the numbers of pneumococci in blood (log CFU/ml; mean ± the standard error of the mean), and Student's t test was used to compare pneumococcal clearance data. A P value of <0.05 was considered significant.

 
Together, our results obtained using {Delta}PAC extend previous observations demonstrating that PspC has an additive role in complement deposition and emphasize the importance of Ply, PspA, and PspC in the establishment of pneumococcal disease. Since other workers have used C3-deficient mice to demonstrate that virulence can be restored in PspA, PspA-Ply, and PspC mutants (13, 31), it would be of value to use complement-deficient mice to investigate complement-independent virulence mechanisms employed by {Delta}PAC. The results of such studies using Ply-, PspA-, and PspC-deficient mutants belonging to different serotypes may identify common complement-dependent and -independent pneumococcal virulence mechanisms.


   ACKNOWLEDGMENTS
 
We are grateful to Moon H. Nahm (supported by grant AI30021) for providing the anticapsular antibody and to Glenn Hoskins for preparing the electron micrographs. We also thank Edwin Swiatlo for his critical reading of the manuscript. Finally, we appreciate the technical assistance of Justin Thornton and Chinwendu Onwubiko.

This study was supported by National Institutes of Health grant AI43653 to L.S.M.


   FOOTNOTES
 
* Corresponding author. Mailing address: Department of Microbiology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216. Phone: (601) 984-6880. Fax: (601) 984-1708. E-mail: LMcDaniel{at}microbio.umsmed.edu. Back

{triangledown} Published ahead of print on 12 January 2007. Back

Editor: J. N. Weiser


   REFERENCES
Top
 Abstract
 Text
 References
 
1. Abeyta, M., G. G. Hardy, and J. Yother. 2003. Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae. Infect. Immun. 71:218-225.[Abstract/Free Full Text]
2. Balachandran, P., A. Brooks-Walter, A. Virolainen-Julkunen, S. K. Hollingshead, and D. E. Briles. 2002. Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect. Immun. 70:2526-2534.[Abstract/Free Full Text]
3. Bosarge, J. R., J. M. Watt, D. O. McDaniel, E. Swiatlo, and L. S. McDaniel. 2001. Genetic immunization with the region encoding the alpha-helical domain of PspA elicits protective immunity against Streptococcus pneumoniae. Infect. Immun. 69:5456-5463.[Abstract/Free Full Text]
4. Briles, D. E., S. K. Hollingshead, E. Swiatlo, A. Brooks-Walter, A. Szalai, A. Virolainen, L. S. McDaniel, K. A. Benton, P. C. Aerts, H. V. Dijk, and M. J. Crain. 2000. Pneumococcal proteins PspA and PspC: their potential for use as vaccines, p. 253-260. In A. Tomasz (ed.), Streptococcus pneumoniae, molecular biology and mechanisms of disease. Mary Ann. Liebert, New York, NY.
5. Brooks-Walter, A., D. E. Briles, and S. K. Hollingshead. 1999. The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia. Infect. Immun. 67:6533-6542.[Abstract/Free Full Text]
6. Cunnion, K. M., P. S. Hair, and E. S. Buescher. 2004. Cleavage of complement C3b to iC3b on the surface of Staphylococcus aureus is mediated by serum complement factor I. Infect. Immun. 72:2858-2863.[Abstract/Free Full Text]
7. Dave, S., S. Carmicle, S. Hammerschmidt, M. K. Pangburn, and L. S. McDaniel. 2004. Dual roles of PspC, a surface protein of Streptococcus pneumoniae, in binding human secretory IgA and factor H. J. Immunol. 173:471-477.[Abstract/Free Full Text]
8. Hardy, G. G., A. D. Magee, C. L. Ventura, M. J. Caimano, and J. Yother. 2001. Essential role for cellular phosphoglucomutase in virulence of type 3 Streptococcus pneumoniae. Infect. Immun. 69:2309-2317.[Abstract/Free Full Text]
9. Iannelli, F., D. Chiavolini, S. Ricci, M. R. Oggioni, and G. Pozzi. 2004. Pneumococcal surface protein C contributes to sepsis caused by Streptococcus pneumoniae in mice. Infect. Immun. 72:3077-3080.[Abstract/Free Full Text]
10. Janulczyk, R., F. Iannelli, A. G. Sjoholm, G. Pozzi, and L. Bjorck. 2000. Hic, a novel surface protein of Streptococcus pneumoniae that interferes with complement function. J. Biol. Chem. 275:37257-37263.[Abstract/Free Full Text]
11. Jarva, H., T. S. Jokiranta, R. Wurzner, and S. Meri. 2003. Complement resistance mechanisms of streptococci. Mol. Immunol. 40:95-107.[CrossRef][Medline]
12. Kang, Y. S., Y. Do, H. K. Lee, S. H. Park, C. Cheong, R. M. Lynch, J. M. Loeffler, R. M. Steinman, and C. G. Park. 2006. A dominant complement fixation pathway for pneumococcal polysaccharides initiated by SIGN-R1 interacting with C1q. Cell 125:47-58.[CrossRef][Medline]
13. Kerr, A. R., G. K. Paterson, J. McCluskey, F. Iannelli, M. R. Oggioni, G. Pozzi, and T. J. Mitchell. 2006. The contribution of PspC to pneumococcal virulence varies between strains and is accomplished by both complement evasion and complement-independent mechanisms. Infect. Immun. 74:5319-5324.[Abstract/Free Full Text]
14. Kharat, A. S., and A. Tomasz. 2006. Drastic reduction in the virulence of Streptococcus pneumoniae expressing type 2 capsular polysaccharide but lacking choline residues in the cell wall. Mol. Microbiol. 60:93-107.[CrossRef][Medline]
15. Kraiczy, P., and R. Wurzner. 2006. Complement escape of human pathogenic bacteria by acquisition of complement regulators. Mol. Immunol. 43:31-44.[CrossRef][Medline]
16. Krushkal, J., O. Bat, and I. Gigli. 2000. Evolutionary relationships among proteins encoded by the regulator of complement activation gene cluster. Mol. Biol. Evol. 17:1718-1730.[Abstract/Free Full Text]
17. Lu, L., Y. Ma, and J. R. Zhang. 2006. Streptococcus pneumoniae recruits complement factor H through the amino terminus of CbpA. J. Biol. Chem. 281:15464-15474.[Abstract/Free Full Text]
18. McDaniel, L. S., W. H. Benjamin, Jr., C. Forman, and D. E. Briles. 1984. Blood clearance by anti-phosphocholine antibodies as a mechanism of protection in experimental pneumococcal bacteremia. J. Immunol. 133:3308-3312.[Abstract]
19. McDaniel, L. S., and E. Swiatlo. 2004. Pneumococcal disease: pathogenesis, treatment, and prevention. Infect. Dis. Clin. Pract. 12:93-98.
20. McDaniel, L. S., J. Yother, M. Vijayakumar, L. McGarry, W. R. Guild, and D. E. Briles. 1987. Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J. Exp. Med. 165:381-394.[Abstract/Free Full Text]
21. Mizrachi Nebenzahl, Y., N. Porat, S. Lifshitz, S. Novick, A. Levi, E. Ling, O. Liron, S. Mordechai, R. K. Sahu, and R. Dagan. 2004. Virulence of Streptococcus pneumoniae may be determined independently of capsular polysaccharide. FEMS Microbiol. Lett. 233:147-152.[CrossRef][Medline]
22. Quin, L. R., S. Carmicle, S. Dave, M. K. Pangburn, J. P. Evenhuis, and L. S. McDaniel. 2005. In vivo binding of complement regulator factor H by Streptococcus pneumoniae. J. Infect. Dis. 192:1996-2003.[CrossRef][Medline]
23. Ren, B., M. A. McCrory, C. Pass, D. C. Bullard, C. M. Ballantyne, Y. Xu, D. E. Briles, and A. J. Szalai. 2004. The virulence function of Streptococcus pneumoniae surface protein A involves inhibition of complement activation and impairment of complement receptor-mediated protection. J. Immunol. 173:7506-7512.[Abstract/Free Full Text]
24. Ren, B., A. J. Szalai, S. K. Hollingshead, and D. E. Briles. 2004. Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect. Immun. 72:114-122.[Abstract/Free Full Text]
25. Rodriguez De Cordoba, S., J. Esparza-Gordillo, E. Goicoechea De Jorge, M. Lopez-Trascasa, and P. Sanchez-Corral. 2004. The human complement factor H: functional roles, genetic variations and disease associations. Mol. Immunol. 41:355-367.[CrossRef][Medline]
26. Rogers, P. D., J. Thornton, K. S. Barker, D. O. McDaniel, G. S. Sacks, E. Swiatlo, and L. S. McDaniel. 2003. Pneumolysin-dependent and -independent gene expression identified by cDNA microarray analysis of THP-1 human mononuclear cells stimulated by Streptococcus pneumoniae. Infect. Immun. 71:2087-2094.[Abstract/Free Full Text]
27. Rosenow, C., P. Ryan, J. N. Weiser, S. Johnson, P. Fontan, A. Ortqvist, and H. R. Masure. 1997. Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae. Mol. Microbiol. 25:819-829.[CrossRef][Medline]
28. Swiatlo, E., L. S. McDaniel, and D. E. Briles. 2004. Choline binding proteins, p. 49-60. In E. I. Tuomanen, T. J. Mitchell, D. A. Morrison, and B. Spratt (ed.), The pneumococcus. ASM Press, Washington, DC.
29. Thornton, J., and L. S. McDaniel. 2005. THP-1 monocytes up-regulate intercellular adhesion molecule 1 in response to pneumolysin from Streptococcus pneumoniae. Infect. Immun. 73:6493-6498.[Abstract/Free Full Text]
30. Yother, J. 2004. Capsules, p. 30-48. In E. I. Tuomanen, T. J. Mitchell, D. A. Morrison, and B. Spratt (ed.), The pneumococcus. ASM Press, Washington, DC.
31. Yuste, J., M. Botto, J. C. Paton, D. W. Holden, and J. S. Brown. 2005. Additive inhibition of complement deposition by pneumolysin and PspA facilitates Streptococcus pneumoniae septicemia. J. Immunol. 175:1813-1819.[Abstract/Free Full Text]

Infection and Immunity, April 2007, p. 2067-2070, Vol. 75, No. 4
0019-9567/07/$08.00+0     doi:10.1128/IAI.01727-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
IAI.01727-06v1
75/4/2067    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Quin, L. R.
Right arrow Articles by McDaniel, L. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Quin, L. R.
Right arrow Articles by McDaniel, L. S.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. J. Virol. Eukaryot. Cell
Microbiol. Mol. Biol. Rev. Clin. Vaccine Immunol. All ASM Journals